脂肪肝对HBeAg阳性慢性乙型肝炎患者疗效的影响

Abstract
Figure/Table
References (16)
Related Citation (4)

Download: PDF (0 KB) HTML (44 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo investigate the impact of fatty liver on antiviral efficacy of Adefovir dipivoxil and the HBsAg′s predictive value in chronic hepatitis B(CHB)patientswith e antigen(HBeAg)positive.Methods71 CHB patientswith HBeAg positive in the hospital outpatient clinic from January 2012 to December 2014 were selected as study subjects,among which,40 cases were simple hepatitis B group,31 cases of hepatitis B with nonalcoholic fatty liver disease (NAFID)were hepatitis B with fatty liver group.Patients of two groups were given oral Adefovir dipivoxil 10 mg/d antiviral therapy for 24 weeks and 36 weeks,negative conversion rate(complete virological response)of HBV-DNA in two groups were observed.According to whether or not to obtain a viral response,simple hepatitis B group and hepatitis B with fatty liver group were divided into complete viral response group and non response group,the change trends of HBV-DNA and HBsAg of two subgroups in two groupswere respectively observed in the treatment process.ResultsAfter treatment for 24 weeks and 36 weeks,HBV-DNA negative conversion rate in the hepatitis B with fatty liver group was 48.4%and 61.3%respectively,significantly lower than 75.0%，82.5%in the simple hepatitis B group,and the difference was statistically significant(P<0.05).In the simple hepatitis B group,HBsAg level of two subgroups after treatment for 24 weeks and 36 weeks was gradually decreased with HBV-DNA level,serum HBV-DNA and HBsAg values after treatment for 24 weeks and 36 weeks in the complete viral response group was significantly lower that in non response group,and the difference was statistically significant(P<0.01).In the hepatitis B with fatty liver group,HBV-DNA level of two subgroups patients after treatment for 24 weeks and 36 weeks decreased significantly,and the difference was statistically significant(P<0.01);HBsAg level during treatment in the hepatitis B with fatty liver group was decreasing,but complete viral response group compared with the non response group after treatment for 24 weeks and 36 weeks,there was no statistically significant difference (P>0.05).Conclusion HBV-DNA negative conversion rate in patientswith hepatitis B can be influenced by complicated with fatty liver;hepatitis B complicated with fatty liver,the change of HBsAg value can not reflect the situation of viral response after treatment.

Key words： Adefovir dipivoxil Nonalcoholic fatty liver disease Chronic hepatitis B

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Yan-ling
	ZHANG Bing
	LIBing-qing
	HE Pei-yuan
	SHIJun-li
	WANG Lei

Cite this article:

WANG Yan-ling,ZHANG Bing,LIBing-qing, et al. Effect of fatty liver on the efficacy of HBeAg positive chronic hepatitis B patients[J]. 中国当代医药, 2016, 23(33): 23-26.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I33/23

[1]	宓余强，刘勇钢.慢性乙型肝炎患者肝脂肪变与肝脏HBsAg 和HBcAg的关系[J].中华消化杂志，2012，32（5）：316-319.
[2]	中华医学会肝病学分会，中华医学会感染病学分会.慢性乙型肝炎防治指南（2010年版）[J].中国肝脏病杂志（电子版），2011，3（1）：40-61.
[3]	中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南（2010年修订版）[J].胃肠病学和肝病学杂志，2010，19（6）：483-487.
[4]	Jarcuska P，Janicko，Kruzliak，etal.Hepatitis B virus infection in patientswithmetabolic syndrome：a complicated relationship.Results of a population based study[J].Eur J Intern Med，2014，25（3）：286-291.
[5]	Zhang RN，Pan Q，Zhang Z，et al.Saturated fatty acid inhibits viral replication in chronic hepatitis B virus infection with nonalcoholic fatty liver disease by toll-like receptor 4-mediated innate immune response[J].Hepat Mon，2015，15（5）：27909.
[6]	Peng D，Han Y，Ding H，et al.Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors[J].Gastroenterol Hepatol，2008，23 （7）：1082-1088.
[7]	徐亮，李萍，史琦玉.肝脂肪变对聚乙二醇干扰素α-2a治疗慢性乙型肝炎疗效的影响[J].中华肝脏病杂志，2015，23（2）：99-102.
[8]	Ates F，Yaln?z M，Alan S.Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B[J].World JGastroenterol，2011，17（40）：4517-4522.
[9]	Jin X，Chen YP，Yang YD，et al.Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B[J].PLoSOne，2012，7（3）：e34198.
[10]	]Bondini S，Kallman J，Wheeler A，et al.Impact of nonalcoholic fatty liver disease on chronic hepatitis B[J].Liver Int，2007，27（5）：607-611.
[11]	Chiang CH，Huang KC.Association between metabolic factors and chronic hepatitis B virus infection[J].World J Gastroenterol，2014，20（23）：7213-7216.
[12]	Yoon S，Jung J，Kim T，et al.Adiponectin，a downstream targetgene of peroxisome proliferator-activated receptorγ，controls hepatitis B virus replication[J].Virology，2011，409（2）：290-298.
[13]	Zhang H，Li H，Yang Y，et al.Differential regulation of host genes including hepatic fatty acid synthase in HBV-transgenic mice[J].J Proteome Res，2013，12（6）：2967-2979.
[14]	黄明清，胡丽，咸建春.慢性乙型肝炎病毒感染患者表面抗原定量检测与病毒载量的相关性[J].中华感染病学杂志，2013，23（14）：3314-3316.
[15]	李明慧，张璐.乙型肝炎表面抗原水平下降预测e抗原阴性患者聚乙二醇干扰素-α-2a治疗中表面抗原消失的研究[J].中华传染病杂志，2015，33（5）：257-260.
[16]	Cheng YL，Wang YJ，Kao WY，et al.Inverse association between hepatitis B virus infection and fatty liver disease：a large-scale study in populations seeking for check-up[J]. PLoSOne，2013，8（8）：72049-72051.